Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

Share Price is delayed by 15 minutes
Get Live Data
194.00    0.00 (0.00%)
Bid:
190.00
Ask:
198.00
Spread: 8.00 (4.211%)
Market Cap: £3.60m
NBB Live PriceLast checked at - London Stock Exchange

Intraday Norman Broadb Share Chart

Trading Update

16 Jan 2025 07:00

RNS Number : 5074T
Norman Broadbent PLC
16 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

Norman Broadbent plc

("Norman Broadbent", the "Company" or the "Group")

 

Trading Update

 

Solid performance in challenging conditions with strong momentum into 2025

 

Norman Broadbent (AIM: NBB), a leading Executive Search and Interim Management firm, provides the following unaudited trading update for the three months ended 31 December 2024 ("Q4 2024") and the year ended 31 December 2024 ("FY24").

 

Q4 2024 Highlights

 

·

Q4 2024 was the Company's strongest quarter of the year with Group Net Fee Income ("NFI") of £2.5m, being more than 10% above the Q1-Q3 2024 average and only slightly down on the comparable period in the preceding year (Q4 2023: £2.6m; Q4 2022: £2.3m)

·

Retainer income, a key driver of recurring revenue, was up 44% year-on-year and 34% higher than the 2024 quarterly average

·

Positive momentum has continued into 2025 with contracted revenues up 40% year-on-year to £2.1m (FY24: £1.5m; FY23: £1.8m)

 

FY 2024 Highlights

 

·

FY 2024 was the Company's second-best annual NFI and underlying EBITDA1 performance in over a decade:

NFI of £9.3m, down 13% on a record FY23 (FY23: £10.5m) and up 27% on FY22 (FY22: £7.3m)

Underlying EBITDA1 expected to be more than £0.25m, down from a record £0.9m in FY23 and up from £0.1m in FY22

·

Loss before tax of approximately £0.2m, reflecting market conditions and strategic investment, represents a decline from FY23's £0.3m profit and an improvement on FY22's loss of £0.3m

·

Year-end net cash2 of £0.1m, down on £0.4m as at 31 December 2023 and considerably up on a net debt2 position of £1.1m as at 31 December 2022

 

1 excludes share based payment charges

2 excluding lease liabilities

 

Kevin Davidson, CEO of Norman Broadbent, commented:

 

"Despite persistent macroeconomic and labour market challenges, the Company delivered its second-best annual trading performance in over a decade, achieving healthy underlying EBITDA1 and, pleasingly, ended the year with a positive net cash position.

 

During the year, we upgraded our talent and selectively grew fee-generating headcount, with more high-calibre individuals due to be joining the Company in the first quarter. We have also strengthened our organisational foundations, moved to new London offices and invested in enhanced systems and processes that will boost productivity across the Group. Our award-winning culture remains a key differentiator, and we continue to earn recognition for fostering an exceptional workplace environment.

 

Whilst we expect market headwinds to persist for at least the first half of 2025, the momentum generated in Q4 FY24 puts us in a strong position relative to many of our peers. Following the successful business turnaround, the Company has demonstrated its resilience and ability to perform in tough conditions, reinforcing our confidence in the future.

 

Looking ahead, we are focused on building on our success to date and driving growth. As part of this, we are exploring ways to expand our international presence, while actively seeking synergistic acquisition opportunities to establish an industry consolidation platform.

 

We remain confident in delivering our previously stated target of £1.25 million of EBITDA in the medium term. Whilst our ability to achieve this in 2025 will be heavily influenced by macro conditions and the timing of any market recovery, the Company is in excellent shape and well placed to rapidly capitalise when conditions improve."

 

For further information please contact:

 

Norman Broadbent plc

Kevin Davidson, CEO

Mehr Malik, CFO

 

+44 (0)20 7484 0000

 

Shore Capital (Nominated Adviser and Broker)

Tom Griffiths / Tom Knibbs (Corporate Advisory)

Henry Willcocks (Corporate Broking)

 

+44 (0)20 7408 4090

Alma (Financial Communications Adviser)

Rebecca Sanders-Hewett

Kinvara Verdon

David Ison

normanbroadbent@almastrategic.com

+44 (0)20 3405 0205

 

About Norman Broadbent:

 

Norman Broadbent (AIM: NBB) is a professional services firm focused on executive search, senior interim management solutions and bespoke leadership advisory services working across the UK and internationally. ​

 

Established as the first UK-headquartered search firm in 1979, the firm has a 40+ year track record of shaping leadership across industries including Consumer, Financial Services, Industrials, Life Sciences, Investor and TMT.​

 

www.normanbroadbent.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFEALAIELIE
Date   Source Headline
20th May 202610:40 amRNSResult of AGM
20th May 20267:00 amRNSAGM Statement
8th May 20267:00 amRNSDirectorate Change
28th Apr 20265:25 pmRNSCourt Approval of Capital Reduction
22nd Apr 20267:00 amRNSPosting of Annual Report & Notice of AGM
21st Apr 20267:00 amRNSQ1 2026 Trading Update
20th Apr 20267:00 amRNSDirectorate Change
31st Mar 20269:11 amRNSTotal Voting Rights
26th Mar 20262:00 pmRNSResult of General Meeting
25th Mar 20267:00 amRNSFinal Results
18th Mar 20268:00 amRNSHolding(s) in Company
10th Mar 20267:00 amRNSProposed Capital Reduction
9th Mar 20269:23 amRNSReplacement- Results Notice/Investor Presentation
9th Mar 20267:00 amRNSNotice of Interim Results & Investor Presentation
25th Feb 20267:00 amRNSAcquisition And Total Voting Rights
6th Feb 20267:03 amRNSDirectorate Change
21st Jan 20267:00 amRNSDirectorate Change
15th Jan 20267:00 amRNSQ4 and FY25 Trading Update
13th Oct 20257:00 amRNSQ3 2025 Trading Update
9th Sep 20257:00 amRNSChange of Auditor
8th Sep 20257:00 amRNSInterim Results
19th Aug 20257:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20257:00 amRNSAppointment of Nominated Adviser and Sole Broker
10th Jul 20257:00 amRNSH1 2025 Trading Update
19th Jun 20252:49 pmRNSNotification of major holdings
19th Jun 20257:00 amRNSDirector/PDMR Shareholding
16th Jun 20257:00 amRNSDirector/PDMR Shareholding
22nd May 202512:58 pmRNSResult of AGM, Capital Reorganisation and TVR
22nd May 20257:00 amRNSAGM Statement
22nd Apr 20257:00 amRNSPosting of ARA & Notice of AGM
2nd Apr 20257:00 amRNSQ1 2025 Trading Update and Final Results
4th Mar 20257:00 amRNSNotice of Results & Investor Presentation
16th Jan 20257:00 amRNSTrading Update
16th Oct 20247:00 amRNSQ3 2024 Trading Update
11th Oct 20244:00 pmRNSDirector/PDMR shareholding
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSChange of Registered Office
9th Sep 20247:00 amRNSInterim Results
19th Aug 20247:00 amRNSNotice of Interim Results & Investor Presentation
22nd Jul 20243:46 pmRNSNotification of major holdings
11th Jul 20247:00 amRNSH1 2024 Trading Update
23rd May 20245:29 pmRNSResult of Annual General Meeting
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.